Sellas’ cancer vaccine extends survival in blood cancer trial, company says
The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow
- ✓The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow
- ✓Patients who received GPS lived a median of 24 months, compared to 14.7 months for those given the best available treatment, Sellas said.
- ✓Civic Domain: Categorized under health public notices.
Sellas Life Sciences said on Tuesday, November 17, 2026 that its experimental vaccine helped patients with a type of blood cancer live longer in a late-stage trial. The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow.
Patients who received GPS lived a median of 24 months, compared to 14.7 months for those given the best available treatment, Sellas said. The company plans to talk to the U.S. Food and Drug Administration about seeking approval for the vaccine.
Its shares were halted in premarket trading.
- •Aspirants and citizens are advised to monitor official notices and circulars issued by The Hindu Health & Medical.
- •Verify all prescribed eligibility criteria, cutoff dates, and authenticated document requirements prior to formal submissions.
- •Track connected examination timetables, vacancy advisories, and administrative gazettes on SuchnaSetu.
| Issuing Authority | The Hindu Health & Medical |
|---|---|
| Topic Category | HEALTH |
| Jurisdiction | All India / National |
| Publication Date | 19 November 2026 |